Effect of tirofiban on myocardial perfusion in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention

WANG Lian,XU Biao,ZHANG Ronglin

DOI: https://doi.org/10.3969/j.issn.1004-8812.2007.04.009

2007-01-01

Abstract:Objective To investigate the effect of glycoprotein Ⅱb/Ⅲa receptor blockade with tirofiban on myocardial perfusion in patients with ST-segment elevated myocardial infarction(STEMI) undergoing primary percutaneous coronary intervention(PCI).Methods Seventy one patients who presented with acute STEMI within 12 hours from onset and received successful primary PCI between January 2005 to December 2006 were enrolled into the study.All patients had angiographic evidence of initial total occlusion of infarct-related artery and finally restored to TIMI 3 flow after PCI.All the patients were grouped into the tirofiban group(n=36) and the control group(n=35) according to whether tirofiban was used or not.Assessment of myocardial perfusion included Myocardial Blush Grades(MBG),and the resolution of the sum of ST-segment elevation(sumSTR) at 90 minutes after the procedure.Left ventricular ejection fraction(EF) was measured one week later.Major adverse cardiac events in hospital and bleeding complications were also assessed.Results Baseline clinical and angiographic characteristics of the two groups were similar.Significant higher rates of MBG 3 were observed in the tirofiban group(69.4% vs 37.1%,P=0.01).Patients received tirofiban were more likely to achieve higher sumSTR(60.6%±26.7% vs 42.2%±35.3%,P=0.03) and complete ST resolution(sumSTR≥70%)(61.1% vs 28.6%,P=0.02).Ejection fraction was also increased markedly in tirofiban group than the control group(55.2%±5.2% vs 51.3%±7.3%,P=0.03).In-hospital major adverse cardiac events were not different between the two groups.There were slightly more minor bleeding complications in the tirofiban group compared with the control(16.7% vs 5.7%,P=0.26).No patient had major bleeding or thrombocytopenia.Conclusion Tirofiban can further ameliorate microvascular perfusion and is safe and feasible for patients with STEMI undergoing primary PCI.